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Gynaecological photomedicine offers new diagnostic and
therapeutic methods based on the interaction of light with
the reproductive organs. One example is photodynamic
therapy (PDT) in which photosensitizers are applied
systemically or topically for selective endometrial ablation.
Several studies describing the potential use of PDT for this
application are reviewed. Basic experimental and clinical
aspects of PDT, such as photosensitizer types, application
modes, irradiation parameters, optical properties of tissues
and photodegradation of photosensitizers are discussed.
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Introduction
Photodynamic therapy (PDT) is an experimental technique for
selective tissue destruction. The process typically involves i.v.
or topical administration of a photosensitizing drug. Although
the photosensitizer is generally retained longer in malignant tissue
(Dougherty, 1984), an accumulation of drug in normal tissue may
also occur. When light of sufficient energy and appropriate
wavelength interacts with the sensitizer, highly reactive oxygen
intermediates are generated. These intermediates, primarily
singlet molecular oxygen, irreversibly oxidize essential cellular
components. The resultant photodestruction of cells and
microvasculature ultimately causes tissue necrosis (Dougherty,
1987).
PDT has been used extensively in the treatment of tumours
(Dougherty, 1984, 1987; DeLaney et al, 1993). Recently,
several groups have studied the potential use of PDT for
endometrial tissue destruction (Schneider etal., 1988a; Petrucco
etal, 1990; Bhatta, 1992; Yang etal., 1993; Chapman et al.,
1993). In view of the growing interest in this new method, this
article summarizes the concepts that are important to the
development of PDT for the study of endometrial physiology and
the treatment of dysfunctional uterine bleeding, endometriosis
and endometrial cancer. The authors explore both in-situ and
ectopic endometrial ablation using a variety of photosensitizers
and light doses.
Characteristics of photosensitizers
The biophysical characteristics of various photosensitizers are
currently an area of intense study (Bhatta et al., 1992; Yang
etal., 1993; Chapman et al., 1993). Perhaps most common
among these are porphyrins, a class of compounds recognized
since the beginning of this century to include a number of effective
photosensitizers (Von Trappenheimer and Jesionek, 1903). The
clinical effect of these photo-active substances in porphyria
cutanea tarda, a cutaneous form of endogenous porphyrin-
opathies, is well known. These observations led to the
development of exogenously administered porphyrins such as
haematoporphyrin derivative (HPD). HPD is a mixture of
porphyrins which tend to be selectively retained in tumours
(Lipson et al., 1961). The purified fraction of HPD is thought
to be primarily composed of a mixture of di-haematoporphyrin
esters and ethers (DHE), and its use has allowed the therapeutic
dose of HPD to be reduced by almost one-half (Kessel, 1990;
Richter et al., 1990a). Additional modification to this compound
has resulted in the development of a more potent photosensitizer,
benzoporphyrin-derivative-monoacid-ring A (BPD-MA), which
is 10—70 times more phototoxic to various cell lines than HPD
(Richter et al., 1987).
Another approach to PDT utilizes 5-aminolevulinic acid
(ALA), a precursor of protoporphyrin IX (Pp IX) in the haem
biosynthetic pathway (Kennedy and Pottier, 1992). Haem
biosynthesis is essential to life and occurs in all aerobic cells.
The slowest step in haem synthesis is the conversion of Pp IX
to haem. Therefore, the exogenous administration of
photodynamically inactive ALA induces the production and
accumulation of Pp IX, a potent photosensitizer. Since only
certain types of cells have a capacity to sensitize substantial
amounts of Pp IX, the use of ALA can provide an additional
element of selectivity to PDT.
Uterine PDT
The human endometrium is particularly well suited to PDT for
a variety of reasons. First, from a practical standpoint, both drug
and light can be easily administered using topical sensitizers and
transvaginal optical fibre illumination. Second, from a clinical
perspective, PDT affects tumour microvasculature (Star et al.,
1986; Chaudhuri et al., 1987; Nelson et al., 1988), and it seems
likely that endometrial microvasculature can respond in a
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Fig. 1. Distribution of di-haematoporphyrin esters and ethers (DHE) after topical administration in rat uterus: (a) bright-field image,
(b) fluorescence image. The fluorescence of DHE is almost identical in glands and stroma, but less in the myometrium.
comparable manner. Third, the requirements for optimizing
endometrial PDT are much less stringent than those for
conventional tumour PDT. This is due to the fact that light
interacts with the endometrium for several millimetres before it
encounters untargeted myometrial, serosal, and peritoneal
structures. As a result, tissue destruction is primarily limited by
our ability to deliver an effective photodynamic light dose
throughout the 2 - 1 0 mm thick endometrial layer.
These factors suggest that endometrial PDT may have several
important medical applications, including treatment of
dysfunctional uterine bleeding and endometriosis, and studying
endometrial regeneration mechanisms. In general, the clinical
management of localized diseases like menorrhagia can be
effectively accomplished using intra-uterine drug administration
(vide infra). The practical benefit of this approach is 2-fold. First,
endometrial drug concentration can be easily and selectively
raised to the highest possible values. Since endometrial thickness
and vascularity depend on hormonal status, uterine light and drug
penetration can be modulated by manipulating hormone
concentrations. Second, intra-uterine drug delivery does not result
in cutaneous photosensitization, an undesirable side-effect of
many i.v. administered sensitizers. This latter feature is a
particularly important consideration in the management of patients
with non-life-threatening conditions.
Application modes
In order to obtain a better understanding of drug distribution in
uterine tissue after various application routes, the relative merits
of i.v., i.p. and intra-uterine administration of the drug Photofrin
(DHE) were evaluated in medically or surgically castrated rats
(Chapman et al., 1993). Tissues were examined using both
microscopy and extraction methods. Extraction of Photofrin from
uterine tissue was conducted according to a modified porphyrin
fecal extraction technique (Rossi and Curnow, 1986). Frozen
sections were analysed by fluorescence microscopy in order to
characterize Photofrin fluorescence and drug distribution in
different uterine layers.
Regardless of delivery route, Photofrin fluorescence gradually
increases in the endometrium over time (Chapman et al., 1993).
In addition, myometrial and stromal drug uptake is minimized
by intra-uterine application. However, it is important to note that
intra-uterine application results in extremely high drug
concentrations in the columnar epithelium (Figure la and b). This
'barrier' effect of the columnar epithelium can be minimized to
some extent by administering Photofrin with a penetration-
enhancing agent such as Azone. Although Photofrin/Azone can
facilitate an increase in endometrial gland and stroma drug
concentrations, the contrast between endometrial and myometrial
concentrations decreases with time (see Steiner et al., 1995).
Finally, despite a 10-fold reduction in dose, intra-uterine
application yielded a significant increase in extracted Photofrin.
This supports the hypothesis that site-specific delivery of
photosensitizer can result in selective retention of the drug at a
much reduced dose. Since systemic application of photosensitizers
inherently involves a higher risk of adverse reactions (primarily
skin photosensitivity), topical drug delivery may be preferable
for endometrial PDT (Chapman et al, 1993).
Kennedy and Pottier (1992) studied Pp IX fluorescence
following the systemic administration of ALA in the mouse
uterus. The endometrium became strongly fluorescent, the
myometrium did not. In a recent article, Judd et al. (1992) studied
fluorescence of rabbit uterine layers following an i.v. injection
of ALA. Endometrial fluorescence peaked 2 - 3 h after injection
and the endometrial layer showed fluorescence levels five times
higher than the myometrium. Similar levels were observed in
our preliminary studies following topical (intra-uterine)
application of ALA. Moreover, a 4:1 fluorescence ratio between
endometrial glands and stroma was observed (Figure 2a and b).
No skin photosensitivity was observed for intra-uterine ALA
delivery.
Basic physical considerations for light apph'cation (PDT)
Porphyrin photosensitizers (e.g. HPD, DHE) are most efficiently
activated by blue light since these wavelengths are generally
222
Photomedicine of the endometrium
Fig. 2. Distribution of protoporphyrin IX after topical application of 5-aminolevulinic acid (ALA) in rabbit uterus: (a) bright-field image,
(b) fluorescence image. The fluorescence of protoporphyrin IX is mainly localized in glands, less in stroma, minimal in myometrium.
absorbed most readily by this class of compounds. However, blue
light tissue penetrance is severely limited by haemoglobin
absorption to a fraction of a millimeter (Figure 3), thus preventing
efficient photodynamic treatment in deeper tissue layers. Since
haemoglobin absorption diminishes at wavelengths >600 nm,
red light can be used to photosensitize deep tissue structures.
Unfortunately, photosensitizers typically absorb red light less
efficiently than blue. For example, Pp EX and DHE red absorption
maxima at 630 nm are nearly 35 times less intense than their
corresponding 405 nm blue peaks (Kimel et al., 1989). Newer
compounds, such as BPD, are designed to absorb light more
readily farther into the red spectral region; the 692 nm BPD molar
extinction coefficient is approximately eight times greater than
that of the 630 nm DHE absortion peak (Richter et al., 1990b).
This is important since the attenuation of light in tissue typically
decreases with increasing wavelength. Consequently, the use of
BPD and compounds with similar photophysical characteristics
can facilitate more efficient treatment at greater tissue depths,
provided, of course, that drug localization occurs in critical
cellular structures. In order to achieve therapeutic effects
comparable to BPD for 630 nm absorbing photosensitizers,
increased light intensities (mW/cm2) or doses (J/cm2) would
have to be used. Of course, several interrelated factors, including
light dose, drug dose, drug localization and photosensitizer
photophysical properties are involved in determining the overall
clinical effectiveness of PDT.
Light propagation through tissue
When tissues are irradiated with 600-800 nm light, - 3 0 % of
the incident dose will be reflected in the surface layers (Svaasand
et al., 1989 and Cilesiz and Welch, 1993). In other words, only
70% of the applied light will propagate into the tissue. Photons
that propagate into the endometrium will be multiply scattered
before they are absorbed. Scattering is caused by optical
inhomogeneities, or, more precisely, by refractive index
discontinuities in cells and tissue. In the near-infrared spectral
regions, scattering is the dominant form of light—tissue
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Fig. 3. Oxyhaemoglobin (Oxy-hb) and haematoporphyrin derivative
(HPD) spectra: HPD exhibits an absorption peak at 630 nm. The
absorption of light by oxyhaemoglobin is small at this wavelength.
interaction. Exceptions include ocular media, such as the cornea,
the lens and the vitreous humour.
Although tissue scattering is predominantly forward-directed,
after a distance of about 1-2 mm, multiple scattering events
produce nearly isotropic light distributions in most tissues. Thus,
the actual photon path length at a given tissue depth is much
longer than the linear distance. This increased path length
enhances the probability for absorption. As a result, scattering
will increase the attenuation of light in the tissue even though
the scattering process itself occurs without loss (Figure 4).
Penetration depth and fluence rate
The intensity of light propagation through tissue decreases
exponentially with distance due to scattering and absorption. The
penetration depth (mm) is defined as the distance corresponding
to a decrease in the optical fluence rate by a factor of \le = 0.37
(where e = 2.718) (Svaasand, 1984). The fluence rate measures
the quantity of photons per second passing through a defined area
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Fig. 4. Diagrammatic presentation of light propagation through
tissue: photons are reflected, scattered and absorbed.
(mW/cm2); the fluence rate is, by definition, equal to the optical
power falling onto an infinitesimally small sphere, divided by
the cross-sectional area of that sphere. If, for example, the optical
penetration depth for a given tissue is 3 mm, the fluence rate
of photons at this depth is 37% of its rate at the surface. If the
distance is doubled to 6 mm, the fluence rate is decreased by
a factor lie2, i.e. to ~ 10% (Figure 5). Since the optical
penetration depth is determined by absorption and scattering
properties, it is a unique parameter which can be used to
characterize a particular tissue.
Back-scattered light in tissues enhances the optical fluence rate
close to the surface. For example, in a non-melanotic skin
tumour, the fluence rate just below the surface is typically 2 - 3
times higher than the incident irradiation. In a hollow organ such
as the uterus, the surface fluence rate may be increased by a factor
of 5 - 6 due to the additional reflection of light from the
surrounding walls (Marijnissen, 1993) (Figure 6). Thus, in PDT
of the endometrium, the fluence rate of the endometrial surface
will generally be much higher than the incident unscattered
irradiation.
The fluence rate in the endometrium is thus dependent on the
reflection conditions at the surface, the incident irradiation, and
the tissue scattering and absorption properties. Since the
absorption and scattering coefficients typically decrease with
increasing wavelength, longer wavelengths have greater tissue
penetrance (Figure 3).
Endometrial optical properties (i.e. absorption and scattering
coefficients) should be determined in order to optimize light
dosimetry for uterine PDT. We have recently conducted optical
property measurements on fresh uterine samples immediately
after hysterectomy (Madsen et al., 1994). Our preliminary results
indicate that bulk tissue absorption and scattering coefficients are,
respectively, in the ranges 0.19-0.52 cm1 and 7.3-9.1 cm1
at 630 run. The corresponding values for the optical penetration
depth are in the region of 2.59—5.11 mm. Although we have
not observed substantial differences in light penetrance for human
endometrium and myometrium, we are exploring this possibility
with additional measurements.
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Fig. 5. Penetration depth: the optical penetration depth (5) of a
given tissue is equal to the distance over which the optical fluence
rate is reduced by a factor Me = 0.37 (where e = 2.718).
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Fig. 6. The fluence rate in tissues of a hollow organ: in a hollow
organ the light level builds up through multiple reflections. The
fluence rate at the tissue surface is 5—6 times higher than the
direct unscattered light from the source.
Optical dose
The optical dose (i.e. the optical fluence) which is deposited in
the tissue is proportional to the incident light power per unit area
(irradiance) and the exposure time. The irradiant optical dose
(J/cm2) is defined by the irradiation (W/cm2) multiplied by the
exposure time in seconds. The tissue optical dose (J/cm2) is
defined as the product of the in-situ fluence rate and the exposure
time. The tissue optical dose decreases exponentially with depth
in the same manner as the fluence rate. As indicated above, the
tissue optical dose depends on the tissue type and geometry and,
just below the surface, usually exceeds the incident fluence rate
by a factor of 2 - 6 . Of course, the optical dose at a given depth
can be enhanced by increasing the incident optical power and/or
prolonging the exposure time.
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Fig. 7. Thermal damage in relation to light intensity: high optical
dose (J/cm2) may be achieved without causing thermal changes in
the tissue by increasing the exposure time.
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Fig. 8. The 'effective' optical dose: because of photobleaching, the
effective optical dose is always smaller than the applied optical
dose. The maximum amount of singlet oxygen generated is limited
to the amount that would have been produced by an optical dose of
75 J/cm2 if the drug had been completely resistant to bleaching.
Thermal damage
PDT is intended to induce photochemical changes at irradiation
levels which do not cause thermal damage. In order to avoid
hyperthermal effects, tissue temperature should be kept below
~43—45°C. A temperature rise of 6—8°C above normal body
temperature corresponds to an incident optical power density in
the range of 100-200 mW/cm2 (Svaasand and Potter, 1989).
In order to achieve deep photodynamic effects with a power
density limited to 100 mW/cm2, the exposure time should be
prolonged (Figure 7).
Photodegradation (bleaching) of the photosensitizer
In response to optical irradiation, photosensitizers tend to
decompose. The concentration of the non-degraded sensitizer
which can participate in the production of singlet oxygen
decreases continuously during irradiation. (Moan, 1986; Svaasand
and Potter, 1992). The efficiency of the singlet oxygen generation
process is, therefore, maximal at the beginning of irradiation,
and it decreases to zero when the sensitizer has been completely
degraded.
This phenomenon can be remedied by introducing the concept
of an 'effective' optical dose. The effective optical dose is
proportional to the amount of in-situ generated singlet oxygen
rather than to the optical fluence. For example, the amount of
active Photofrin is reduced by photobleaching to Me = 0.37 after
application of an optical dose of 75 J/cm2. An optical dose
several times larger than this value will 'bleach' the
photosensitizer almost completely; an infinitely large optical dose
will only produce a finite amount of singlet oxygen. The total
amount of singlet oxygen generated by an infinitely large optical
dose will, in fact, be equal to the amount of singlet oxygen that
would have been produced by an optical dose of 75 J/cm2, if
Photofrin had been completely resistant to bleaching. Bleaching
is, on the other hand, insignificant if the optical dose is much
smaller than 75 J/cm2; in this case, the effective optical dose
will be approximately equal to the real optical dose (Figure 8).
The effective optical dose will, therefore, be close to the upper
limit of 75 J/cm2 in the region close to the irradiated surface
where the optical fluence is high. Bleaching will play an
insignificant role in the deeper layers where the fluence has fallen
off. In the case of endometrial destruction, bleaching will limit
the 'over-kill' in the upper layer of the endometrium; at the same
time, it has only an insignificant effect on the depth of necrosis.
Conclusion
In the past 5 years, several studies in rats and rabbits have
suggested that PDT may offer a new approach for selective
endometrial ablation. Different elements of PDT, such as the type
and concentration of photosensitizer, the interval between drug
application and light treatment (3-72 h), drug delivery mode
(systemic versus topical), light sources (gold vapour laser, argon
pumped dye laser, incoherent filtered red light), light doses and
light delivery modes, have been studied. As one might expect,
these are just a few of the parameters which affect the
development of viable treatment protocols in humans. Based on
our preliminary results, PDT appears to be a promising,
minimally invasive alternative to surgery for treatment of
dysfunctional uterine bleeding. However, additional studies must
be undertaken to evaluate carefully factors associated with
functional loss, long-term tissue regeneration, and selective
binding of photosensitizers to endometrial structures. Ultimately,
these efforts may lead to the development of a novel clinical
technique as well as to contributions to our understanding of
endometrial physiology and the implantation process.
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